There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

President-elect Donald Trump wants to buy the territory from Denmark, which says it’s not for sale. DealBook asked experts ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating ...

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Here are 11 healthcare industry lawsuits, settlements and legal developments that Becker's has reported since Jan. 3: ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

President-elect Donald Trump 's threat to "tariff Denmark at a very high level" if it refuses to give up Greenland could ...